Cargando…
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes
Although cytarabine has been widely considered as one of the chemotherapy drugs for high-risk myelodysplastic syndromes (MDS), the overall response rate is only approximately 20-30%. Nuclear factor erythroid 2-related factor 2 (NRF2, also called NFE2L2) has been shown to play a pivotal role in preve...
Autores principales: | Lin, Peipei, Ren, Yanling, Yan, Xiaomei, Luo, Yingwan, Zhang, Hua, Kesarwani, Meenu, Bu, Jiachen, Zhan, Di, Zhou, Yile, Tang, Yuting, Zhu, Shuanghong, Xu, Weilai, Zhou, Xinping, Mei, Chen, Ma, Liya, Ye, Li, Hu, Chao, Azam, Mohammad, Ding, Wei, Jin, Jie, Huang, Gang, Tong, Hongyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395322/ https://www.ncbi.nlm.nih.gov/pubmed/30262569 http://dx.doi.org/10.3324/haematol.2018.197749 |
Ejemplares similares
-
Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes
por: Jiang, Lingxu, et al.
Publicado: (2019) -
Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes
por: Yan, Xuefen, et al.
Publicado: (2021) -
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
por: Wang, Lu, et al.
Publicado: (2022) -
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
por: Ye, Li, et al.
Publicado: (2017) -
Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
por: Zhou, Xinping, et al.
Publicado: (2023)